Relay Therapeutics Jumps 16% on New Clinical Data for Its Only Drug That Matters
NEW YORK, April 8 —
Relay Therapeutics (RLAY) surged 16% to $13.48 on news that Zovegalisib will get its first clinical data readout in vascular anomalies.
- RLAY shares up 16% ahead of initial clinical data presentation at the ISSVA World Congress 2026
- The stock trades at $13.48 with just $15mn in TTM revenue and a negative forward P/E of -8.7x
- ISSVA presentation date and specific efficacy and safety data from the vascular anomalies trial are the next catalysts
What Actually Happened
Relay is bringing Zovegalisib, a PI3Kα inhibitor originally developed for oncology, into a completely different therapeutic area: vascular anomalies. These are rare disorders of blood vessel formation that currently have limited treatment options. The company plans to present initial clinical data at the ISSVA World Congress 2026, and the market is pricing in optimism before anyone has seen a single slide.
The interesting part is the mechanism. PI3Kα is a known driver of certain vascular malformations, not just tumors. So this isn't a random indication grab. There's biological logic here. Alpelisib, Novartis's PI3Kα inhibitor, already showed activity in a related condition called PIK3CA-related overgrowth spectrum, which gave the entire class a proof of concept in non-oncology settings. Relay is now testing whether Zovegalisib can carve out its own space in this neighborhood.
The Catch
A 16% move on the promise of "initial data" is the market paying full price for a lottery ticket. We haven't seen response rates. We haven't seen safety. We haven't seen how many patients were in this trial. Relay generates $15mn in TTM revenue and burns cash at a pace that makes the negative forward earnings multiple almost meaningless as a valuation tool. The stock is a bet on pipeline, not on a business.
There's also the Novartis shadow. Alpelisib already has FDA approval in PIK3CA-related overgrowth spectrum under the brand name Vijoice. If Zovegalisib's vascular anomaly data looks similar but not clearly better, Relay will need to explain why doctors would switch. Being second into a rare disease with a drug in the same class is a tough pitch without a differentiated profile.
Bottom Line
This news makes RLAY more interesting, not necessarily more valuable. A biotech with $15mn in revenue doesn't need a second indication to dream about. It needs one indication to work, decisively. The vascular anomalies angle is scientifically credible and expands the story, but the 16% pop is entirely built on anticipation. The number to watch is the objective response rate at ISSVA. Anything below what Alpelisib showed in adjacent conditions and this trade unwinds fast.
For a deeper look at Relay Therapeutics' fundamentals and pipeline valuation, generate a free RLAY report on Basis Report.
Basis Report does not hold positions in securities discussed. This is not investment advice.